Huang Li-Juan, Lin Jen-Hui, Tsai Jung-Heng, Chu Yen-Yin, Chen Yen-Wen, Chen Shun-Li, Chen Shu-Hui
Department of Chemistry, National Cheng Kung University, Tainan, Taiwan.
Department of Communication Engineering, National Central University, Jhongli, Taiwan.
J Chromatogr A. 2014 Dec 5;1371:136-45. doi: 10.1016/j.chroma.2014.10.046. Epub 2014 Nov 1.
We reported an improved combinatorial approach for identifying site-specific O-glycosylation using both glycan cleaved and non-cleaved methods. In this approach, a non-reducing β-elimination kit coupled with non-specific enzymes performed efficient digestion, O-glycan cleavage, and partial dephosphorylation without significant side reactions, thus enabling an automatic database search for the cleaved O-glycosylation or serine/threonine (S/T) phosphorylation sites. From the same sample concurrently prepared without β-elimination, the corresponding intact O-glycopeptides were mapped by accurate precursor ion mass using an in-house glycan database majorly composed of GalNAc (mucin-type) core and the retention-time shift (ΔRt). Each glycopeptide assignment was verified by the detection of glycan-specific fragments using collision-induced dissociation (CID) to estimate False Discovery Rate (FDR). Using fetuin as a model, all identified S/T elimination sites were matched to multiple intact glycopeptides with a 31% FDR. This considerably reduced to 0% FDR by ΔRt filtering. This approach was then applied to a protein mixture composed of therapeutic Factor IX and Enbrel(®) mixed with fetuin and kappa-casein. A total of 26 glycosylation sites each of which corresponds to 1-4 glycans were positively mapped and confirmed. The FDR decreased from 33% to 3.3% by ΔRt filtering and exclusion of repeated peptide tags that covered the same glycosylation sites. Moreover, the phosphorylation and O-glycosylation on the same site such as T159 of Factor IX and T170 of kappa-casein were able to be unambiguously differentiated. Thus, our approach is useful for in-depth characterization of site-specific O-glycosylation of a simple mixture such as protein-based therapeutics.
我们报道了一种改进的组合方法,用于使用聚糖切割和未切割方法鉴定位点特异性O-糖基化。在这种方法中,一种非还原β-消除试剂盒与非特异性酶相结合,可进行高效消化、O-聚糖切割和部分去磷酸化,且无明显副反应,从而能够自动在数据库中搜索切割后的O-糖基化或丝氨酸/苏氨酸(S/T)磷酸化位点。从同时制备的未进行β-消除的同一样品中,使用主要由GalNAc(粘蛋白型)核心组成的内部聚糖数据库和保留时间偏移(ΔRt),通过精确的前体离子质量对相应的完整O-糖肽进行定位。通过使用碰撞诱导解离(CID)检测聚糖特异性片段来估计错误发现率(FDR),从而验证每个糖肽的归属。以胎球蛋白为模型,所有鉴定出的S/T消除位点与多个完整糖肽匹配,FDR为31%。通过ΔRt过滤,FDR大幅降至0%。然后将该方法应用于由治疗性凝血因子IX和恩利(Enbrel®)与胎球蛋白和κ-酪蛋白混合而成的蛋白质混合物。总共确定了26个糖基化位点,每个位点对应1-4个聚糖,并得到了证实。通过ΔRt过滤和排除覆盖相同糖基化位点的重复肽标签,FDR从33%降至3.3%。此外,能够明确区分同一位点上的磷酸化和O-糖基化,如凝血因子IX的T159和κ-酪蛋白 的T170。因此,我们的方法对于深入表征基于蛋白质的治疗药物等简单混合物的位点特异性O-糖基化很有用。